Co-Authors
This is a "connection" page, showing publications co-authored by Rebecca Berhanu and Cynthia Firnhaber.
Connection Strength
0,611
-
Discordant rifampicin susceptibility results are associated with Xpert® MTB/RIF probe B and probe binding delay. Int J Tuberc Lung Dis. 2019 03 01; 23(3):358-362.
Score: 0,166
-
Can patients afford the cost of treatment for multidrug-resistant tuberculosis in Ethiopia? Int J Tuberc Lung Dis. 2018 08 01; 22(8):358-362.
Score: 0,160
-
A call to action: Addressing the reproductive health needs of women with drug-resistant tuberculosis. S Afr Med J. 2016 Mar 17; 106(4):30-1.
Score: 0,136
-
Direct costs of managing adverse drug reactions during rifampicin-resistant tuberculosis treatment in South Africa. Int J Tuberc Lung Dis. 2018 04 01; 22(4):393-398.
Score: 0,039
-
Persistently high early mortality despite rapid diagnostics for drug-resistant tuberculosis cases in South Africa. Int J Tuberc Lung Dis. 2017 10 01; 21(10):1106-1111.
Score: 0,038
-
Adverse drug reactions during drug-resistant TB treatment in high HIV prevalence settings: a systematic review and meta-analysis. J Antimicrob Chemother. 2017 07 01; 72(7):1871-1879.
Score: 0,037
-
Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study. BMC Infect Dis. 2016 Oct 21; 16(1):593.
Score: 0,035